<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0123-9015</journal-id>
<journal-title><![CDATA[Revista Colombiana de Cancerología]]></journal-title>
<abbrev-journal-title><![CDATA[rev.colomb.cancerol.]]></abbrev-journal-title>
<issn>0123-9015</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cancerología E.S.E.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0123-90152017000200095</article-id>
<article-id pub-id-type="doi">10.1016/j.rccan.2017.03.002</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Supervivencia del cáncer de próstata resistente a la castración en la práctica clínica y el papel del tratamiento]]></article-title>
<article-title xml:lang="en"><![CDATA[Survival of Castration-Resistant Prostate Cancer in Clinical Practice and the Role of Treatment]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Angulo]]></surname>
<given-names><![CDATA[Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Romero]]></surname>
<given-names><![CDATA[Ignacio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz-Puente]]></surname>
<given-names><![CDATA[María Teresa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Enrech]]></surname>
<given-names><![CDATA[Santos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díez]]></surname>
<given-names><![CDATA[Raúl]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[Teresa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Europea de Madrid Servicios de Urología Hospital Universitario de Getafe]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Europea de Madrid Oncología Médica Hospital Universitario de Getafe]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Europea de Madrid Farmacia Hospitalaria Hospital Universitario de Getafe]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>21</volume>
<numero>2</numero>
<fpage>95</fpage>
<lpage>103</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0123-90152017000200095&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0123-90152017000200095&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0123-90152017000200095&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Evaluar en un contexto de práctica clínica la ventaja de supervivencia para pacientes con cáncer de próstata resistente a castración (CPRC) tratado activamente con diversos tratamientos que incluyen acetato de abiraterona (AA) y prednisona con o sin docetaxel.  Material y método:  Se analiza la supervivencia de pacientes con CPRC y se compara un grupo tratado con AA y prednisona (n = 33) con un control histórico formado por pacientes consecutivos tratados una década antes en la misma institución exclusivamente con retirada de antiandrógeno y medidas paliativas (n = 31). Se analizan variables clínico-patológicas predictivas de pronóstico en la población activamente tratada. Se evalúa la respuesta global a AA y el intervalo libre de progresión radiológica.  Resultados:  La supervivencia cáncer específica a 2 años fue 79% para pacientes tratados activamente y 17,2% para control (log-rank, p &lt; 0,0001). Cinco de 13 pacientes con AA post-docetaxel (38,5%) recibieron después de AA quimioterapia de segunda línea (4 cabazitaxel y 1 vinorelbina) y 1 (7,7%) hormonoterapia con enzalutamida. Tres de 20 pacientes tratados con AA sin quimioterapia (15%) recibieron enzalutamida y solo 1 (5%) fue tratado con docetaxel. Los pacientes de menor edad (&lt;65años; p = 0,02) y sin metástasis al diagnóstico (p = 0,04) tuvieron mejor pronóstico. Aquellos de PSA más alto (&gt;45ng/ml; p = 0,09) y patrón de Gleason 5 en la biopsia se comportaron de manera más desfavorable. Globalmente el 75,8% tuvieron respuesta a AA (80% pre- y 69,2% post-quimioterapia; p = 0,1) y el 52,4% estuvieron libre de progresión radiológica al año (47,9% pre y 49,8% post-quimioterapia; log-rank, p = 0,3).  Conclusión:  El tratamiento de pacientes con CPRC prolonga la expectativa de supervivencia en un entorno de práctica clínica y es posible identificar factores predictivos de pronóstico en estos pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Purpose:  To assess, in a clinical practice context, the survival advantages of patients with castration-resistant prostate cancer (CRPC) actively treated with several treatments that include abiraterone acetate (AA) and prednisone, with or without docetaxel.  Material and Methods:  An analysis was performed on patient survival with CRPC, and was compared to a group treated with AA and prednisone (n = 33), with a historical control treated exclusively with anti-androgen withdrawal and palliative measures (n = 31). In the population actively treated, variables predictive of prognosis were analysed, as well as an evaluation of the overall response to AA and radiographic progression-free survival.  Results:  Cancer-specific survival at 2 years was 79% for patients actively treated and 17.2% for control group (P&lt;.0001). Five (38.5%) of 13 patients treated with AA post-docetaxel received second-line chemotherapy after AA (4 cabazitaxel, 1 vinorelbine), and one (7.7%) enzalutamide. Three (15%) of 20 patients treated with AA without chemotherapy received enzalutamide and 1(5%) docetaxel. The younger patients (&lt;65yrs; P=.02) without metastases at diagnosis (P=.04) had better prognoses. Patients with higher PSA levels (&gt;45 ng/ml; P=.09) and a Gleason pattern 5 in the biopsy had less favourable outcomes. There was a 75.8% over response to AA (80% preand 69.2%post-chemotherapy; P=.1), and 69.2%post-chemotherapy; P=.1), and 52.4% were radiographic progression-free at 1 year of treatment (47.9% pre- and 49.8% post-chemotherapy; P=.3).  Conclusion:  Treatment of CRPC patients extends survival expectations in a clinical practice setting and prognostic predictors can be identified in these patients.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Cáncer de próstata resistente a la castración]]></kwd>
<kwd lng="es"><![CDATA[Tratamiento, Acetato de abiraterona]]></kwd>
<kwd lng="es"><![CDATA[Quimioterapia sistemática]]></kwd>
<kwd lng="es"><![CDATA[Supervivencia]]></kwd>
<kwd lng="es"><![CDATA[Factores pronóstico]]></kwd>
<kwd lng="en"><![CDATA[Castration-resistant prostate cancer]]></kwd>
<kwd lng="en"><![CDATA[Treatment]]></kwd>
<kwd lng="en"><![CDATA[Abiraterone Acetate]]></kwd>
<kwd lng="en"><![CDATA[Systemic chemotherapy]]></kwd>
<kwd lng="en"><![CDATA[Survival]]></kwd>
<kwd lng="en"><![CDATA[Prognostic factors]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[National practice patterns and time trends in androgen ablation for localized prostate cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cooperberg]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Grossfeld]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Lubeck]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Carroll]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
</person-group>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2003</year>
<volume>95</volume>
<page-range>981-9</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Variability of the urological clinical practice in prostate cancer in Spain]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Núñez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Angulo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Chapado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Portillo]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Villavicencio]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Actas Urol Esp]]></source>
<year>2012</year>
<volume>36</volume>
<page-range>333-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Androgen deprivation therapy for prostate cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Singer]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Golijanin]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Miyamoto]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Messing]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
</person-group>
<source><![CDATA[Expert Opin Pharma-cother]]></source>
<year>2008</year>
<volume>9</volume>
<page-range>211-28</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Redefining hormone resistance in prostate cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoimes]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
</person-group>
<source><![CDATA[Ther AdvMed Oncol]]></source>
<year>2010</year>
<volume>2</volume>
<page-range>107-23</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mechanisms of androgen-refractory prostate cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Debes]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Tindall]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2004</year>
<volume>351</volume>
<page-range>1488-90</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mechanisms underlying the development of androgen-independent prostate cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pienta]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bradley]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2006</year>
<volume>12</volume>
<page-range>1665-71</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A DNA hypermethylation profile reveals new potential biomarkers for prostate cancer diagnosis and prognosis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ashour]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Angulo]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Andrés]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Alelú]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[González-Corpas]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Toledo]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<source><![CDATA[Prostate]]></source>
<year>2014</year>
<volume>74</volume>
<page-range>1171-82</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Clinical and biomarker correlates of androgen-independent locally aggressive prostate cancer with limited metastatic potential]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Assikis]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
<name>
<surname><![CDATA[Do]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Wen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Cho-Vega]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Brisbay]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2004</year>
<volume>10</volume>
<page-range>6770-8</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tannock]]></surname>
<given-names><![CDATA[IF]]></given-names>
</name>
<name>
<surname><![CDATA[de Wit]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Berry]]></surname>
<given-names><![CDATA[WR]]></given-names>
</name>
<name>
<surname><![CDATA[Horti]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pluzanska]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chi]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2004</year>
<volume>351</volume>
<page-range>1502-12</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Advances in prostate cancer chemotherapy a new era begins]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pienta]]></surname>
<given-names><![CDATA[KJ]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2005</year>
<volume>55</volume>
<page-range>300-18</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Abiraterone and increased survival in metastatic prostate cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Bono]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Logothetis]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fizazi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[North]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>364</volume>
<page-range>1995-2005</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Abiraterone acetate for treatment of metasta-tic castration-resistant prostate cancer final overall survival analysis of the COU-AA-301 randomised double-blind placebo-controlled phase 3 study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fizazi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Scher]]></surname>
<given-names><![CDATA[HI]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Logothetis]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chi]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet Oncol]]></source>
<year>2012</year>
<volume>13</volume>
<page-range>983-92</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Abiraterone in metastatic prostate cancer without previous chemotherapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[de Bono]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Logothetis]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[De Souza]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2013</year>
<volume>368</volume>
<page-range>138-48</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer patient-reported outcome results of a randomised phase 3 trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Basch]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Autio]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mulders]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Shore]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kheoh]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet Oncol]]></source>
<year>2013</year>
<volume>14</volume>
<page-range>1193-9</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Heidenreich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bastian]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bellmunt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bolla]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Joniau]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Association of Urology EAU guidelines on prostate cancer Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer]]></article-title>
<collab>Van der Kwast T.Mason M.Matveev V.Wiegel T.Zattoni F.Mottet N</collab>
<source><![CDATA[Eur Urol]]></source>
<year>2014</year>
<volume>65</volume>
<page-range>467-79</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer a pooled analysis of seven prospective clinical trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Regan]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[O'Donnell EK]]></surname>
</name>
<name>
<surname><![CDATA[Kelly]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
<name>
<surname><![CDATA[HalabiS]]></surname>
</name>
<name>
<surname><![CDATA[Berry]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[UrakamiS]]></surname>
</name>
</person-group>
<source><![CDATA[Ann Oncol]]></source>
<year>2010</year>
<volume>21</volume>
<page-range>312-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cáncer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oudard]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tropic]]></surname>
</name>
</person-group>
<source><![CDATA[Future Oncol]]></source>
<year>2011</year>
<volume>7</volume>
<page-range>497-506</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Increased survival with enzalutamide in prostate cancer after chemotherapy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scher]]></surname>
<given-names><![CDATA[HI]]></given-names>
</name>
<name>
<surname><![CDATA[Fizazi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Saad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Taplin]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Sternberg]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2012</year>
<volume>367</volume>
<page-range>1187-97</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Castration-resistant prostate cancer From new pathophysiology to new treatment]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sridhar]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Freedland]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gleave]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Higano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mulders]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Urol]]></source>
<year>2016</year>
<volume>65</volume>
<page-range>289-99</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Individualized decision-making for older men with prostate cancer Balancing cancer control with treatment consequences across the clinical spectrum]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sajid]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mohile]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
<name>
<surname><![CDATA[Szmulewitz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Posadas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dale]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[Semin Oncol]]></source>
<year>2011</year>
<volume>38</volume>
<page-range>309-25</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A wealth of new options A case presentation of the management of castration-recurrent prostate cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beach]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Somer]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffman-Censits]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[YN]]></given-names>
</name>
<name>
<surname><![CDATA[Pli-meck]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Semin Oncol]]></source>
<year>2012</year>
<volume>39</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prognostic factors for survival among Caucasian African-American and Hispanic men with androgen-independent prostate cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wyatt]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Ortiz]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Wood]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Logothetis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pettaway]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Natl Med Assoc]]></source>
<year>2004</year>
<volume>96</volume>
<page-range>1587-93</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prognostic factors in stage D2 prostate cancer important implications for future trials results of a cooperative intergroup study (INT 0036) The National Cancer Institute Intergroup Study #0036]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eisenberger]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Wolf]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Blumenstein]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[McLeod]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Benson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Semin Oncol]]></source>
<year>1994</year>
<volume>21</volume>
<page-range>613-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Metastatic carcinoma of the prostate identifying prognostic groups using recursive partitioning]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Glass]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Tangen]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[J Urol]]></source>
<year>2003</year>
<volume>169</volume>
<page-range>164-9</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beardo-Villar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Ledo-Cepero]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gavira-Moreno]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Soto-Delgado]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Soto-Villalba]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Alvarez-Ossorio]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<source><![CDATA[Actas Urol Esp]]></source>
<year>2014</year>
<volume>38</volume>
<page-range>339-45</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of prior endocrine therapy on radiographic progression-free survival in patients with chemotherapy-naive metastatic castration-resistant prostate cancer Results from COU-AA-302]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oudard]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kheoh]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Small]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mulders]]></surname>
<given-names><![CDATA[PFA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<volume>32</volume>
<numero>^s4</numero>
<issue>^s4</issue>
<supplement>4</supplement>
</nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Response to androgen signaling-directed therapy after treatment with abiraterone acetate in patients with metastatic castration-resistant prostate cancer Post hoc analysis of study COU-AA-302]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Matheny]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Saad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rathkopf]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Mulders]]></surname>
<given-names><![CDATA[PFA]]></given-names>
</name>
<name>
<surname><![CDATA[de Bono]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<volume>32</volume>
<numero>^s4</numero>
<issue>^s4</issue>
<supplement>4</supplement>
</nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa) An ECOG-led phase III randomized trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sweeney]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Carducci]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Jarrard]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Eisenberger]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<volume>32</volume>
<numero>^s5</numero>
<issue>^s5</issue>
<supplement>5</supplement>
</nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Does Gleason score predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate Phase 3 trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fizazi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Flaig]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ohlmann]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Scher]]></surname>
<given-names><![CDATA[HI]]></given-names>
</name>
<name>
<surname><![CDATA[de Bono]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Rathkopf]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<numero>32^s4</numero>
<issue>32^s4</issue>
<supplement>4</supplement>
</nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Association of alkaline phosphatase with clinical outcomes in chemotherapy-naive patients with metastatic castration-resistant prostate cancer Results from COU-AA-302]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[EY]]></given-names>
</name>
<name>
<surname><![CDATA[Saad]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Londhe]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shore]]></surname>
<given-names><![CDATA[ND]]></given-names>
</name>
<name>
<surname><![CDATA[Van Poppel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Rathkopf]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Oncol]]></source>
<year>2014</year>
<volume>32</volume>
<numero>^s4</numero>
<issue>^s4</issue>
<supplement>4</supplement>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
